Article(id=1329835223094768210, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835073559441697, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2024.02.014, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1698422400000, receivedDateStr=2023-10-28, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794987024328, onlineDateStr=2026-11-18, pubDate=1707494400000, pubDateStr=2024-02-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794987024328, onlineIssueDateStr=2026-11-18, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794987024328, creator=13701087609, updateTime=1794987024328, updator=13701087609, issue=Issue{id=1329835073559441697, tenantId=1146029695717560320, journalId=1319690329412173987, year='2024', volume='45', issue='2', pageStart='107', pageEnd='227', issueExtLink='null', onlineDate='null', pubDate='1707494400000', pubDateStr='2024-02-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794986988677, creator='13701087609', updateTime=1794988212209, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1329840205898560208, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835073559441697, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1329840205902754513, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1329835073559441697, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=192, endPage=197, ext={EN=ArticleExt(id=1329835223329649235, articleId=1329835223094768210, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Clinical research progress on the novel insulin formulations, columnId=1325221194584162830, journalTitle=World Clinical Drug, columnName=Review, runingTitle=null, highlight=null, articleAbstract=

Diabetes mellitus (DM) has always been one of the major global public health issues. Insulin has been an irreplaceable drug for controlling blood sugar in DM patients for a long time. In order to obtain better hypoglycemic effect and improve patient compliance, insulin preparations are constantly updated and iterated. This article reviewed the research progress in weekly basal insulin, oral insulin administration route and insulin compound preparation, in order to provide reference for clinical practice.

, authors=Baixue DONG1, Yi REN2, Jing YANG2, *, authorsList=Baixue DONG, Yi REN, Jing YANG, authorCompany=null, correspAuthors=Jing YANG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1329835223547753044, articleId=1329835223094768210, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=新型胰岛素制剂临床研究进展, columnId=1325221194743546384, journalTitle=世界临床药物, columnName=综述评论, runingTitle=null, highlight=null, articleAbstract=

糖尿病(diabetes mellitus,DM)一直以来是全球重大公共卫生课题之一,胰岛素是DM患者长久以来控制血糖不可替代的药物。为获得更佳降糖效果,提高患者依从性,胰岛素制剂不断更新迭代。现对胰岛素周制剂、胰岛素口服给药途径及胰岛素复方制剂等研究进展作一综述,旨在为临床提供参考。

, authors=董白雪1, 任毅2, 杨静2, *, authorsList=董白雪, 任毅, 杨静, authorCompany=null, correspAuthors=杨静, authorNote=

董白雪,硕士研究生,研究方向:内分泌与代谢相关疾病研究。

, correspAuthorsNote=
杨静,博士生导师,教授,主任医师,研究方向:内分泌代谢遗传。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=pXuFN6JNm8Uo2g3A/RWTbw==, magXml=KXy1KLW8ZvJKn7l6P01JuQ==, pdfUrl=null, pdf=00kIq6EImWb+obu9C5NVlA==, pdfFileSize=1574685, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=v3PD1z5t70IuDSSrlrxIkw==, mapNumber=null, fund=null)}, authors=[Author(id=1329835223900074588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835223992349278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835223900074588, language=EN, stringName=Baixue DONG, firstName=Baixue, middleName=null, lastName=DONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.First School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835224059458143, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835223900074588, language=CN, stringName=董白雪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.山西医科大学第一临床医学院,山西 太原 030001, bio={"content":"

董白雪,硕士研究生,研究方向:内分泌与代谢相关疾病研究。

"}, bioImg=null, bioContent=

董白雪,硕士研究生,研究方向:内分泌与代谢相关疾病研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835223732302421, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=1., ext=[AuthorCompanyExt(id=1329835223749079638, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223732302421, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223757468247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223732302421, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.山西医科大学第一临床医学院,山西 太原 030001)])]), Author(id=1329835224151732834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835224290144868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224151732834, language=EN, stringName=Yi REN, firstName=Yi, middleName=null, lastName=REN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835224344670821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224151732834, language=CN, stringName=任毅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.山医科大学第一医院内分泌科,山西 太原 030001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835223820382808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=2., ext=[AuthorCompanyExt(id=1329835223828771417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223837160026, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山医科大学第一医院内分泌科,山西 太原 030001)])]), Author(id=1329835224445334119, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835224533414505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224445334119, language=EN, stringName=Jing YANG, firstName=Jing, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835224625689194, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224445334119, language=CN, stringName=杨静, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.山医科大学第一医院内分泌科,山西 太原 030001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835223820382808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=2., ext=[AuthorCompanyExt(id=1329835223828771417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223837160026, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山医科大学第一医院内分泌科,山西 太原 030001)])])], keywords=[Keyword(id=1329835224713769579, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=EN, orderNo=1, keyword=diabetes mellitus), Keyword(id=1329835224776684140, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=EN, orderNo=2, keyword=basal insulin), Keyword(id=1329835224852181613, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=EN, orderNo=3, keyword=oral insulin), Keyword(id=1329835226508931694, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=EN, orderNo=4, keyword=weekly basal insulin), Keyword(id=1329835226584429167, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=CN, orderNo=1, keyword=糖尿病), Keyword(id=1329835226664120944, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=CN, orderNo=2, keyword=基础胰岛素), Keyword(id=1329835226727035505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=CN, orderNo=3, keyword=口服胰岛素), Keyword(id=1329835226794144370, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, language=CN, orderNo=4, keyword=胰岛素周制剂)], refs=[Reference(id=1329835226970305140, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=Liu J, Liu M, Chai Z, et al. Projected rapid growth in diabetes disease burden and economic burden in China: a spatiotemporal study from 2020 to 2030[J]. Lancet Reg Health West Pac, 2023, 33: 100700., articleTitle=null, refAbstract=null), Reference(id=1329835227045802613, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=Retnakaran R, Zinman B. The ongoing evolution of basal insulin therapy over 100 years and its promise for the future[J]. Diabetes Obes Metab, 2022, 24(Suppl 1): 17-26., articleTitle=null, refAbstract=null), Reference(id=1329835227112911478, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=Cheng AYY, Patel DK, Reid TS, et al. Differentiating basal insulin preparations: understanding how they work explains why they are different[J]. Adv Ther, 2019, 36(5): 1018-1030., articleTitle=null, refAbstract=null), Reference(id=1329835227188408951, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=Schloot NC, Hood RC, Corrigan SM, et al. Concentrated insulins in current clinical practice[J]. Diabetes Res Clin Pract, 2019, 148: 93-101., articleTitle=null, refAbstract=null), Reference(id=1329835227247129208, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=McCrimmon RJ. ONWARDS and upwards for basal insulin[J]. Lancet, 2023, 401(10392): 1904-1905., articleTitle=null, refAbstract=null), Reference(id=1329835227356181113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them[J]. Diabetes Obes Metab, 2018, 20(3): 488-496., articleTitle=null, refAbstract=null), Reference(id=1329835227444261498, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=Guzman SJ. A behavioral perspective of therapeutic inertia: a look at the transition to insulin therapy[J]. Diabetes Spectr, 2020, 33(1): 38-43., articleTitle=null, refAbstract=null), Reference(id=1329835227515564667, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosenstock J, Del Prato S. Basal weekly insulins: the way of the future![J]. Metabolism, 2022, 126: 154924., articleTitle=null, refAbstract=null), Reference(id=1329835227586867836, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=Singh AK, Singh A, Singh R, et al. Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials[J]. Diabetes Metab Syndr, 2022, 16(9): 102615., articleTitle=null, refAbstract=null), Reference(id=1329835227666559613, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=Moyers JS, Hansen RJ, Day JW, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein[J]. J Pharmacol Exp Ther, 2022, 382(3): 346-355., articleTitle=null, refAbstract=null), Reference(id=1329835227729474174, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing[J]. Br Med J Open Diabetes Res Care, 2021, 9(1): e002301., articleTitle=null, refAbstract=null), Reference(id=1329835227800777343, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosenstock J, Bajaj H S, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment[J]. N Engl J Med, 2020, 383(22): 2107-2116., articleTitle=null, refAbstract=null), Reference(id=1329835227863691904, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=Kjeldsen TB, Hubálek F, Hjørringgaard CU, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans[J]. J Med Chem, 2021, 64(13): 8942-8950., articleTitle=null, refAbstract=null), Reference(id=1329835227934995073, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=Bajaj HS, Goldenberg RM. Insulin icodec weekly: a basal insulin analogue for type 2 diabetes[J]. touchREV Endocrinol, 2023, 19(1): 4-6., articleTitle=null, refAbstract=null), Reference(id=1329835228006298242, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin[J]. N Engl J Med, 2023, 389(4): 297-308., articleTitle=null, refAbstract=null), Reference(id=1329835228065018499, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial[J]. J Am Med Assoc, 2023, 330(3): 228-237., articleTitle=null, refAbstract=null), Reference(id=1329835228119544452, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=Bajaj HS, Bajaj HS, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial[J]. Ann Intern Med, 2023, 176(11): 1476-1485., articleTitle=null, refAbstract=null), Reference(id=1329835228186653317, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Philis-Tsimikas A, Bajaj HS, Begtrup K, et al. Rationale and design of the phase 3a development programme (ONWARDS 1 – 6 trials) investigating once-weekly insulin icodec in diabetes[J]. Diabetes Obes Metab, 2023, 25(2): 331-341., articleTitle=null, refAbstract=null), Reference(id=1329835228241179270, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial[J]. Lancet Diabetes Endocrinol, 2023, 11(6): 414-425., articleTitle=null, refAbstract=null), Reference(id=1329835228295705223, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial[J]. Lancet, 2023, 401(10392): 1929-1940., articleTitle=null, refAbstract=null), Reference(id=1329835228358619784, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Heise T, Chien JY, Beals JM, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora α), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes[J]. Diabetes Obes Metab, 2023, 25(4): 1080-1090., articleTitle=null, refAbstract=null), Reference(id=1329835228425728649, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=Moyers JS, Volk CB, Zhang C, et al. Cellular internalization and localization of once-weekly basal insulin Fc[J]. Diabetol Stoff wechs, 2022, 17(S1): S25-S26., articleTitle=null, refAbstract=null), Reference(id=1329835228488643210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-weekly basal insulin fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial[J]. Diabetes Care, 2023, 46(5): 1060-1067., articleTitle=null, refAbstract=null), Reference(id=1329835228572529291, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=Frias J, Chien J, Zhang QY, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study[J]. Lancet Diabetes Endocrinol, 2023, 11(3): 158-168., articleTitle=null, refAbstract=null), Reference(id=1329835228635443852, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=Elsayed A, Al-Remawi M, Jaber N, et al. Advances in buccal and oral delivery of insulin[J]. Int J Pharm, 2023, 633: 122623., articleTitle=null, refAbstract=null), Reference(id=1329835228698358413, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=Spoorthi Shetty S, Halagali P, Johnson AP, et al. Oral insulin delivery: barriers, strategies, and formulation approaches: a comprehensive review[J]. Int J Biol Macromol, 2023, 242(Pt 3): 125114., articleTitle=null, refAbstract=null), Reference(id=1329835228769661582, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=Wang M, Wang C, Ren S, et al. Versatile oral insulin delivery nanosystems: from materials to nanostructures: international journal of molecular sciences[J]. Int J Mol Sci, 2022, 23(6): 3362., articleTitle=null, refAbstract=null), Reference(id=1329835228954210959, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=Iyer G, Dyawanapelly S, Jain R, et al. An overview of oral insulin delivery strategies (OIDS)[J]. Int J Biol Macromol, 2022, 208: 565-585., articleTitle=null, refAbstract=null), Reference(id=1329835229012931216, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Eldor R, Francis BH, Fleming A, et al. Oral insulin (ORMD-0801) in type 2 diabetes mellitus: a dose-finding 12-week randomized placebo-controlled study[J]. Diabetes Obes Metab, 2023, 25(4): 943-952., articleTitle=null, refAbstract=null), Reference(id=1329835229105205905, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局药品审评中心. 受理品种信息: CXSS2300021[EB/OL]. (2023-04-25) [2023-08-25]. https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d., articleTitle=null, refAbstract=null), Reference(id=1329835229184897682, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Inc OP. Oramed signs term sheet with HTIT to create a joint venture to advance oral drug delivery technology globally[EB/OL]. (2023-08-30) [2023-08-24]. https://oramed.com/oramed-signs-term-sheet-with-htit-to-create-a-joint-venture-to-advance-oral-drug-delivery-technology-globally/., articleTitle=null, refAbstract=null), Reference(id=1329835229239423635, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis[J]. Lancet, 2014, 384(9961): 2228-2234., articleTitle=null, refAbstract=null), Reference(id=1329835229323309716, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=Inman TR, Plyushko E, Austin NP, et al. The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes[J]. Ther Adv Endocrinol Metab, 2018, 9(5): 151-155., articleTitle=null, refAbstract=null), Reference(id=1329835230933922453, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=编写组德谷胰岛素利拉鲁肽注射液临床应用专家指导建议. 德谷胰岛素利拉鲁肽注射液临床应用专家指导建议[J]. 中华糖尿病杂志, 2023, 15(3): 209-215., articleTitle=null, refAbstract=null), Reference(id=1329835231017808534, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=Gough SCL, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes[J]. Lancet Diabetes Endocrinol, 2014, 2(11): 885-893., articleTitle=null, refAbstract=null), Reference(id=1329835231097500311, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)[J]. Diabetes Care, 2014, 37(11): 2926-2933., articleTitle=null, refAbstract=null), Reference(id=1329835231164609176, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL Ⅲ randomized clinical trial[J]. Diabetes Ther, 2017, 8(1): 101-114., articleTitle=null, refAbstract=null), Reference(id=1329835231248495257, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL Ⅳtrial[J]. Diabet Med, 2017, 34(2): 189-196., articleTitle=null, refAbstract=null), Reference(id=1329835231303021210, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=Lingvay I, Pérez Manghi F, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL Ⅴ randomized clinical trial[J]. J Am Med Assoc, 2016, 315(9): 898-907., articleTitle=null, refAbstract=null), Reference(id=1329835231365935771, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL Ⅵ randomized clinical trial[J]. Diabetes Obes Metab, 2017, 19(6): 858-865., articleTitle=null, refAbstract=null), Reference(id=1329835231424656028, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=Philis-Tsimikas A, Billings LK, Busch R, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes[J]. Diabetes Obes Metab, 2019, 21(6): 1399-1408., articleTitle=null, refAbstract=null), Reference(id=1329835231500153501, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=Billings LK, Doshi A, Gouet D, et al. Efficacy and Safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; DUAL Ⅶ randomized clinical trial[J]. Diabetes Care, 2018, 41(5): 1009-1016., articleTitle=null, refAbstract=null), Reference(id=1329835231571456670, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=Vilsbøll T, Blevins TC, Jodar E, et al. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin[J]. Diabetes Obes Metab, 2019, 21(6): 1506-1512., articleTitle=null, refAbstract=null), Reference(id=1329835231646954143, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=Wei R, Wang W, Huang X, et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the Chinese type 2 diabetes patients[J]. Diabetol Metab Syndr, 2023, 15(1): 173., articleTitle=null, refAbstract=null), Reference(id=1329835231709868704, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=Niemoeller E, Souhami E, Wu Y, et al. iGlarLixi reduces glycated hemoglobin to a greater extent than basal insulin regardless of levels at screening: post hoc analysis of LixiLan-L[J]. Diabetes Ther, 2018, 9(1): 373-382., articleTitle=null, refAbstract=null), Reference(id=1329835231772783265, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=Giorgino F, Shaunik A, Liu M, et al. Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: a post hoc analysis of the LixiLan-L trial[J]. Diabetes Obes Metab, 2019, 21(12): 2712-2717., articleTitle=null, refAbstract=null), Reference(id=1329835231839892130, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial[J]. Diabetes Care, 2021, 44(10): 2361-2370., articleTitle=null, refAbstract=null), Reference(id=1329835231907000995, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1RA in type 2 diabetes inadequately controlled by GLP-1RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial[J]. Diabetes Care, 2019, 42(11): 2108-2116., articleTitle=null, refAbstract=null)], funds=[Fund(id=1329835226886419059, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, awardId=201804D131044, language=CN, fundingSource=山西省科技成果转化引导专项项目(201804D131044), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1329835223732302421, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=1., ext=[AuthorCompanyExt(id=1329835223749079638, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223732302421, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223757468247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223732302421, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.山西医科大学第一临床医学院,山西 太原 030001)]), AuthorCompany(id=1329835223820382808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=2., ext=[AuthorCompanyExt(id=1329835223828771417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223837160026, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山医科大学第一医院内分泌科,山西 太原 030001)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.02.014, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.02.014, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2024.02.014, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2024.02.014, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1707494400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
新型胰岛素制剂临床研究进展
董白雪 1 , 任毅 2 , 杨静 2, *
世界临床药物 | 综述评论 2024,45(2): 192-197
收起
收藏切换
世界临床药物 |综述评论 2024 , 45 (2) : 192 -197
新型胰岛素制剂临床研究进展
全屏
[Author(id=1329835223900074588, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835223992349278, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835223900074588, language=EN, stringName=Baixue DONG, firstName=Baixue, middleName=null, lastName=DONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.First School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835224059458143, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835223900074588, language=CN, stringName=董白雪, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=1, address=1.山西医科大学第一临床医学院,山西 太原 030001, bio={"content":"

董白雪,硕士研究生,研究方向:内分泌与代谢相关疾病研究。

"}, bioImg=null, bioContent=

董白雪,硕士研究生,研究方向:内分泌与代谢相关疾病研究。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835223732302421, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=1., ext=[AuthorCompanyExt(id=1329835223749079638, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223732302421, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.First School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223757468247, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223732302421, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=1.山西医科大学第一临床医学院,山西 太原 030001)])]), Author(id=1329835224151732834, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1329835224290144868, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224151732834, language=EN, stringName=Yi REN, firstName=Yi, middleName=null, lastName=REN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835224344670821, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224151732834, language=CN, stringName=任毅, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, address=2.山医科大学第一医院内分泌科,山西 太原 030001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835223820382808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=2., ext=[AuthorCompanyExt(id=1329835223828771417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223837160026, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山医科大学第一医院内分泌科,山西 太原 030001)])]), Author(id=1329835224445334119, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1329835224533414505, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224445334119, language=EN, stringName=Jing YANG, firstName=Jing, middleName=null, lastName=YANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1329835224625689194, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, authorId=1329835224445334119, language=CN, stringName=杨静, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=2, *, address=2.山医科大学第一医院内分泌科,山西 太原 030001, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1329835223820382808, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, xref=2., ext=[AuthorCompanyExt(id=1329835223828771417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China), AuthorCompanyExt(id=1329835223837160026, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1329835223094768210, companyId=1329835223820382808, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=2.山医科大学第一医院内分泌科,山西 太原 030001)])])]
董白雪1, 任毅2, 杨静2, *
作者信息
  • 1.山西医科大学第一临床医学院,山西 太原 030001
  • 2.山医科大学第一医院内分泌科,山西 太原 030001
通讯作者:
杨静,博士生导师,教授,主任医师,研究方向:内分泌代谢遗传。
作者简介:

董白雪,硕士研究生,研究方向:内分泌与代谢相关疾病研究。

Clinical research progress on the novel insulin formulations
Baixue DONG1, Yi REN2, Jing YANG2, *
Affiliations
  • 1.First School of Clinical Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
  • 2.Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
出版时间: 2024-02-10 doi: 10.13683/j.wph.2024.02.014
文章导航
收藏切换

糖尿病(diabetes mellitus,DM)一直以来是全球重大公共卫生课题之一,胰岛素是DM患者长久以来控制血糖不可替代的药物。为获得更佳降糖效果,提高患者依从性,胰岛素制剂不断更新迭代。现对胰岛素周制剂、胰岛素口服给药途径及胰岛素复方制剂等研究进展作一综述,旨在为临床提供参考。

糖尿病  /  基础胰岛素  /  口服胰岛素  /  胰岛素周制剂

Diabetes mellitus (DM) has always been one of the major global public health issues. Insulin has been an irreplaceable drug for controlling blood sugar in DM patients for a long time. In order to obtain better hypoglycemic effect and improve patient compliance, insulin preparations are constantly updated and iterated. This article reviewed the research progress in weekly basal insulin, oral insulin administration route and insulin compound preparation, in order to provide reference for clinical practice.

diabetes mellitus  /  basal insulin  /  oral insulin  /  weekly basal insulin
董白雪, 任毅, 杨静. 新型胰岛素制剂临床研究进展. 世界临床药物, 2024 , 45 (2) : 192 -197 . DOI: 10.13683/j.wph.2024.02.014
Baixue DONG, Yi REN, Jing YANG. Clinical research progress on the novel insulin formulations[J]. World Clinical Drug, 2024 , 45 (2) : 192 -197 . DOI: 10.13683/j.wph.2024.02.014
  • 山西省科技成果转化引导专项项目(201804D131044)
参考文献 引证文献
排序方式:
[1]
Liu J, Liu M, Chai Z, et al. Projected rapid growth in diabetes disease burden and economic burden in China: a spatiotemporal study from 2020 to 2030[J]. Lancet Reg Health West Pac, 2023, 33: 100700.
[2]
Retnakaran R, Zinman B. The ongoing evolution of basal insulin therapy over 100 years and its promise for the future[J]. Diabetes Obes Metab, 2022, 24(Suppl 1): 17-26.
[3]
Cheng AYY, Patel DK, Reid TS, et al. Differentiating basal insulin preparations: understanding how they work explains why they are different[J]. Adv Ther, 2019, 36(5): 1018-1030.
[4]
Schloot NC, Hood RC, Corrigan SM, et al. Concentrated insulins in current clinical practice[J]. Diabetes Res Clin Pract, 2019, 148: 93-101.
[5]
McCrimmon RJ. ONWARDS and upwards for basal insulin[J]. Lancet, 2023, 401(10392): 1904-1905.
[6]
Russell-Jones D, Pouwer F, Khunti K. Identification of barriers to insulin therapy and approaches to overcoming them[J]. Diabetes Obes Metab, 2018, 20(3): 488-496.
[7]
Guzman SJ. A behavioral perspective of therapeutic inertia: a look at the transition to insulin therapy[J]. Diabetes Spectr, 2020, 33(1): 38-43.
[8]
Rosenstock J, Del Prato S. Basal weekly insulins: the way of the future![J]. Metabolism, 2022, 126: 154924.
[9]
Singh AK, Singh A, Singh R, et al. Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials[J]. Diabetes Metab Syndr, 2022, 16(9): 102615.
[10]
Moyers JS, Hansen RJ, Day JW, et al. Preclinical characterization of LY3209590, a novel weekly basal insulin Fc-fusion protein[J]. J Pharmacol Exp Ther, 2022, 382(3): 346-355.
[11]
Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing[J]. Br Med J Open Diabetes Res Care, 2021, 9(1): e002301.
[12]
Rosenstock J, Bajaj H S, Janež A, et al. Once-weekly insulin for type 2 diabetes without previous insulin treatment[J]. N Engl J Med, 2020, 383(22): 2107-2116.
[13]
Kjeldsen TB, Hubálek F, Hjørringgaard CU, et al. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans[J]. J Med Chem, 2021, 64(13): 8942-8950.
[14]
Bajaj HS, Goldenberg RM. Insulin icodec weekly: a basal insulin analogue for type 2 diabetes[J]. touchREV Endocrinol, 2023, 19(1): 4-6.
[15]
Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin[J]. N Engl J Med, 2023, 389(4): 297-308.
[16]
Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial[J]. J Am Med Assoc, 2023, 330(3): 228-237.
[17]
Bajaj HS, Bajaj HS, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial[J]. Ann Intern Med, 2023, 176(11): 1476-1485.
[18]
Philis-Tsimikas A, Bajaj HS, Begtrup K, et al. Rationale and design of the phase 3a development programme (ONWARDS 1 – 6 trials) investigating once-weekly insulin icodec in diabetes[J]. Diabetes Obes Metab, 2023, 25(2): 331-341.
[19]
Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial[J]. Lancet Diabetes Endocrinol, 2023, 11(6): 414-425.
[20]
Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial[J]. Lancet, 2023, 401(10392): 1929-1940.
[21]
Heise T, Chien JY, Beals JM, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora α), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes[J]. Diabetes Obes Metab, 2023, 25(4): 1080-1090.
[22]
Moyers JS, Volk CB, Zhang C, et al. Cellular internalization and localization of once-weekly basal insulin Fc[J]. Diabetol Stoff wechs, 2022, 17(S1): S25-S26.
[23]
Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-weekly basal insulin fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial[J]. Diabetes Care, 2023, 46(5): 1060-1067.
[24]
Frias J, Chien J, Zhang QY, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study[J]. Lancet Diabetes Endocrinol, 2023, 11(3): 158-168.
[25]
Elsayed A, Al-Remawi M, Jaber N, et al. Advances in buccal and oral delivery of insulin[J]. Int J Pharm, 2023, 633: 122623.
[26]
Spoorthi Shetty S, Halagali P, Johnson AP, et al. Oral insulin delivery: barriers, strategies, and formulation approaches: a comprehensive review[J]. Int J Biol Macromol, 2023, 242(Pt 3): 125114.
[27]
Wang M, Wang C, Ren S, et al. Versatile oral insulin delivery nanosystems: from materials to nanostructures: international journal of molecular sciences[J]. Int J Mol Sci, 2022, 23(6): 3362.
[28]
Iyer G, Dyawanapelly S, Jain R, et al. An overview of oral insulin delivery strategies (OIDS)[J]. Int J Biol Macromol, 2022, 208: 565-585.
[29]
Eldor R, Francis BH, Fleming A, et al. Oral insulin (ORMD-0801) in type 2 diabetes mellitus: a dose-finding 12-week randomized placebo-controlled study[J]. Diabetes Obes Metab, 2023, 25(4): 943-952.
[30]
国家药品监督管理局药品审评中心. 受理品种信息: CXSS2300021[EB/OL]. (2023-04-25) [2023-08-25]. https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d.
[31]
Inc OP. Oramed signs term sheet with HTIT to create a joint venture to advance oral drug delivery technology globally[EB/OL]. (2023-08-30) [2023-08-24]. https://oramed.com/oramed-signs-term-sheet-with-htit-to-create-a-joint-venture-to-advance-oral-drug-delivery-technology-globally/.
[32]
Eng C, Kramer CK, Zinman B, et al. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis[J]. Lancet, 2014, 384(9961): 2228-2234.
[33]
Inman TR, Plyushko E, Austin NP, et al. The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes[J]. Ther Adv Endocrinol Metab, 2018, 9(5): 151-155.
[34]
编写组德谷胰岛素利拉鲁肽注射液临床应用专家指导建议. 德谷胰岛素利拉鲁肽注射液临床应用专家指导建议[J]. 中华糖尿病杂志, 2023, 15(3): 209-215.
[35]
Gough SCL, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes[J]. Lancet Diabetes Endocrinol, 2014, 2(11): 885-893.
[36]
Buse JB, Vilsbøll T, Thurman J, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira)[J]. Diabetes Care, 2014, 37(11): 2926-2933.
[37]
Linjawi S, Bode BW, Chaykin LB, et al. The efficacy of IDegLira (insulin degludec/liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL Ⅲ randomized clinical trial[J]. Diabetes Ther, 2017, 8(1): 101-114.
[38]
Rodbard HW, Bode BW, Harris SB, et al. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL Ⅳtrial[J]. Diabet Med, 2017, 34(2): 189-196.
[39]
Lingvay I, Pérez Manghi F, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL Ⅴ randomized clinical trial[J]. J Am Med Assoc, 2016, 315(9): 898-907.
[40]
Harris SB, Kocsis G, Prager R, et al. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL Ⅵ randomized clinical trial[J]. Diabetes Obes Metab, 2017, 19(6): 858-865.
[41]
Philis-Tsimikas A, Billings LK, Busch R, et al. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: a randomized clinical trial in people with uncontrolled type 2 diabetes[J]. Diabetes Obes Metab, 2019, 21(6): 1399-1408.
[42]
Billings LK, Doshi A, Gouet D, et al. Efficacy and Safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin; DUAL Ⅶ randomized clinical trial[J]. Diabetes Care, 2018, 41(5): 1009-1016.
[43]
Vilsbøll T, Blevins TC, Jodar E, et al. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin[J]. Diabetes Obes Metab, 2019, 21(6): 1506-1512.
[44]
Wei R, Wang W, Huang X, et al. Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the Chinese type 2 diabetes patients[J]. Diabetol Metab Syndr, 2023, 15(1): 173.
[45]
Niemoeller E, Souhami E, Wu Y, et al. iGlarLixi reduces glycated hemoglobin to a greater extent than basal insulin regardless of levels at screening: post hoc analysis of LixiLan-L[J]. Diabetes Ther, 2018, 9(1): 373-382.
[46]
Giorgino F, Shaunik A, Liu M, et al. Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: a post hoc analysis of the LixiLan-L trial[J]. Diabetes Obes Metab, 2019, 21(12): 2712-2717.
[47]
Rosenstock J, Emral R, Sauque-Reyna L, et al. Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial[J]. Diabetes Care, 2021, 44(10): 2361-2370.
[48]
Blonde L, Rosenstock J, Del Prato S, et al. Switching to iGlarLixi versus continuing daily or weekly GLP-1RA in type 2 diabetes inadequately controlled by GLP-1RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial[J]. Diabetes Care, 2019, 42(11): 2108-2116.
2024年第45卷第2期
13
0
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2024.02.014
  • 接收时间:2023-10-28
  • 首发时间:2026-11-18
  • 出版时间:2024-02-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2023-10-28
基金
山西省科技成果转化引导专项项目(201804D131044)
作者信息
    1.山西医科大学第一临床医学院,山西 太原 030001
    2.山医科大学第一医院内分泌科,山西 太原 030001

通讯作者:

杨静,博士生导师,教授,主任医师,研究方向:内分泌代谢遗传。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2024.02.014
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏